Screener
OptimizeRx OPRX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 73.2%+8.8pp | 70%+14.1pp | 67.3%+27.0pp | 65.3%+30.1pp | 64.4%+33.3pp | |
| Operating margin | 11.1%— | 13.2%— | 10.7%— | —— | —— | |
| Net margin | 4.7%+14.1pp | 6.4%+26.4pp | 4.7%+41.4pp | 0%+47.5pp | -9.4%+29.6pp | |
| Returns | ||||||
| Return on equity | 3.7%+11.9pp | 5.6%+18.5pp | 4.2%+20.7pp | 0%+21.0pp | -8.2%+6.9pp | |
| Return on invested capital | 5.7%— | 7.6%— | 6.4%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.6×0.0× | 0.6×+0.2× | 0.6×+0.3× | 0.7×+0.3× | 0.6×+0.3× | |
| Liquidity | ||||||
| Current ratio | 5.6×+3.0× | 5.4×+2.6× | 3×+0.2× | 3×-0.2× | 2.6×-0.5× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.2×-0.1× | 0.2×-0.1× | 0.2×-0.1× | 0.2×-0.1× | |
| Net debt / EBITDA | -0.3×— | 0.2×— | 0.2×— | —— | —— | |
| Per Share | ||||||
| Book value per share | $6.98+11.2% | $6.91+9.7% | $6.75+5.6% | $6.28+0.6% | $6.27-5.4% | |
| Valuation | ||||||
| Market capitalization | $157.85M-53.5% | $117.83M-26.4% | $228.53M+155% | $380.58M+169% | $238.59M+30.6% | |
| Price / earnings | 34.3×-9,954× | 17.2×— | 44.5×— | 11,193.6×— | —— | |
| Price / sales | 1.6×-1.5× | 1.1×-1.0× | 2.1×+0.5× | 3.5×+0.7× | 2.3×-1.7× | |
| Price / book | 1.2×-1.6× | 0.9×-0.5× | 1.8×+1.0× | 3.1×+1.9× | 2×+0.5× | |
| EV / EBITDA | 10.1×— | 6.6×— | 14.4×— | —— | —— |
FAQ
- What are OptimizeRx's profit margins?
- OptimizeRx (OPRX) runs a 73.2% gross margin and a 11.1% operating margin, with a 4.7% net margin.
- Where do OptimizeRx's ratios come from?
- Every ratio is computed from OptimizeRx's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
